NCT07600775Not yet recruitingPhase 1
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI). The main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- First submitted
- 15 May 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 19 Jan 2027
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Tuberculosis, HIV
- NCT number
- NCT07600775
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 14
- From 1 Sept 2026 to the primary completion date, 19 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
- Has a history of cancer (malignancy)
- Has a history of active TB
- Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus
Other
- The main exclusion criteria include but are not limited to the following:
- Has a diagnosis of LTBI made in the context of an outbreak/contact-tracing investigation
- Has a current or anticipated immunocompromised state
Who the study is looking for
- The main inclusion criteria include but are not limited to the following:
- Has a diagnosis of untreated latent tuberculosis infection (LTBI)
- Has no symptoms of active tuberculosis (TB)
- Has never received treatment for TB or LTBI
- Other than having LTBI, is in good health
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.